Metastatic breast cancer (HER2 positive) in None combination There with were trastuzumab Aus and and May listed July listed Dec Pertuzumab Perjeta® 21 Yes 61 no funding no funding NZ docetaxel in 2013 July 2015 2013 2016 patients who have in the not received past prior treatment or No outside No May May listed Sept no Plerixafor Mozobil® Aus 2 No 0 funding response 2010 Nov 2015 2016 registration restrictions 2013 Relapsed Patient no no Aus and refractory paid for July Nov March registration Pomalidomide 12 Yes 16 no funding NZ multiple up to 2 2014 2014, no 2015 no myeloma cycles listed Aug funding funding 2015
registration Pertuzumab Perjeta® Aus and NZ 21 Yes Metastatic breast cancer (HER2 positive) in combination with trastuzumab and docetaxel in patients who have not received prior treatment or 61 None There were in the past May 2013 listed July 2015 no funding July 2013 listed Dec 2016 no funding Plerixafor Mozobil® Aus 2 No No response 0 No May 2010 Nov 2013 outside funding restrictions May 2015 listed Sept 2016 no registration Pomalidomide Aus and NZ 12 Yes Relapsed refractory multiple myeloma 16 Patient paid for up to 2 cycles July 2014 Nov 2014, listed Aug 2015 no no funding March 2015 no funding no no funding
1-s2.0-S0168851017303457-mmc1.docx